Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pemafibrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 848259-27-8, Pemafibrate [inn], (r)-k-13675, K-13675, (r)-, (r)-2-(3-((benzo[d]oxazol-2-yl(3-(4-methoxyphenoxy)propyl)amino)methyl)phenoxy)butanoic acid, Chembl247951
    Molecular Formula
    C28H30N2O6
    Molecular Weight
    490.5  g/mol
    InChI Key
    ZHKNLJLMDFQVHJ-RUZDIDTESA-N
    FDA UNII
    17VGG92R23
    Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid
    2.1.2 InChI
    InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
    2.1.3 InChI Key
    ZHKNLJLMDFQVHJ-RUZDIDTESA-N
    2.1.4 Canonical SMILES
    CCC(C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
    2.1.5 Isomeric SMILES
    CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3
    2.2 Other Identifiers
    2.2.1 UNII
    17VGG92R23
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (r)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) Butanoic Acid

    2. K 13675

    3. K-13675

    4. K-13675-d11

    5. K-13675-d7

    6. K13675

    2.3.2 Depositor-Supplied Synonyms

    1. 848259-27-8

    2. Pemafibrate [inn]

    3. (r)-k-13675

    4. K-13675, (r)-

    5. (r)-2-(3-((benzo[d]oxazol-2-yl(3-(4-methoxyphenoxy)propyl)amino)methyl)phenoxy)butanoic Acid

    6. Chembl247951

    7. Cas#848259-27-8

    8. 17vgg92r23

    9. Pemafibrate (jan)

    10. Pemafibrate [jan]

    11. (2r)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic Acid

    12. (2~{r})-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic Acid

    13. Unii-17vgg92r23

    14. Parmodia (tn)

    15. P7f

    16. Pemafibrate [mi]

    17. K-877

    18. (r)-k 13675

    19. Pemafibrate [who-dd]

    20. Schembl2766188

    21. Dtxsid00233891

    22. Glxc-25532

    23. Bcp20864

    24. Ex-a1919

    25. Yib25927

    26. Bdbm50214899

    27. Cs-6084

    28. Db15212

    29. Ac-36249

    30. Hy-17618

    31. D10711

    32. A914970

    33. (r)-k-13675(r)-k-13675

    34. Q27251943

    35. K-877; (r)-k 13675; Cs-2768

    36. K-877; K877; K 877; (r)-k 13675; (r)-k13675; (r)k-13675

    37. (r)-2-(3-((n-(benzoxazol-2-yl)-n-(3-(4-methoxyphenoxy)propyl)amino)methyl)phenoxy)butanoic Acid

    38. (r)-2-[3-[n-(benzoxazol-2-yl)-n-(3-(4-methoxyphenoxy)propyl)aminomethyl]phenoxy]butyric Acid

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 490.5 g/mol
    Molecular Formula C28H30N2O6
    XLogP36.2
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count13
    Exact Mass490.21038668 g/mol
    Monoisotopic Mass490.21038668 g/mol
    Topological Polar Surface Area94.3 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity658
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Prevention of cardiovascular events in patients with elevated triglycerides levels, Treatment of hypertriglyceridaemia